This is why I am interested in how this Valens deal will effect Oil sales in the short to medium term.
Trials and results are still some time off. But if they go to plan, we will be in a sweet spot.
I see that a US company is now allowed to sell medical cannabis for OSA. But, it has no clinically proven supportive documentation. Owning IP and having a clinically proven product, with the market in its infancy, is where we want to be. it is the difference maker.
We just need to sit back and wait.
IHL Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held